Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on August 8, 2018. The filing serves to announce financial results for the quarter ended June 30, 2018. The registrant is incorporated in Delaware and maintains its principal executive offices in Vancouver, B.C., Canada. The company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information is furnished but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2018) for actual financial figures and operational updates.
- Verify the company's status as an emerging growth company and its implications for financial reporting standards.
- Confirm the specific details of the quarter ended June 30, 2018, as the 8-K body contains no quantitative data.